Vitamin D and Critically Ill Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01636232|
Recruitment Status : Completed
First Posted : July 10, 2012
Last Update Posted : June 6, 2016
|Condition or disease|
|Systemic Inflammatory Response Syndrome Sepsis|
|Study Type :||Observational|
|Actual Enrollment :||234 participants|
|Observational Model:||Case Control|
|Official Title:||Vitamin D Levels and Risk of Infection, Assessment for Disease Severity, and Predictor of Mortality in the Chinese Intensive Care Units: a Prospective Cohort Study|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||December 2011|
|Actual Study Completion Date :||December 2011|
ICU sepsis group
The ICU sepsis group consisting of 105 critically-ill cases diagnosed with sepsis upon admission and sampled within the first 24h of their ICU stay.
ICU control group
the ICU control group including 51 critically-ill cases in whom sepsis was clinically excluded and from whom samples were taken upon admission.
healthy control group
the healthy control group composed of 50 healthy control outpatients. For the healthy control outpatients, possibilities of acute or past chronic diseases were excluded. Moreover, we made sure that the healthy control subjects had not been hospitalized or taken vitamin-based substitutive drugs in the last 12 months, and proved normal in physical checkups and lab examinations.
- Patients Outcome [ Time Frame: 28 days ]The survival time of patients more than 28 days is defined as survival. The survival time of patients less than 28 days is defined as death.
- Patients Outcome [ Time Frame: 90 days ]The survival time of patients more than 90 days is defined as survival. The survival time of patients less than 90 days is defined as death.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01636232
|Chinese PLA General Hospital|
|Beijing, China, 100853|
|Study Director:||Lixin Xie, MD||Department Of Respiratory Diseases, Chinese PLA General Hospital|